Nobivac NXT Feline-3 Rabies (Canada)

Company: Merck Animal Health

RABIES VACCINE, RNA PARTICLE

FOR ANIMAL USE ONLY

IN THE ABSENCE OF A VETERINARIAN-CLIENT-PATIENT RELATIONSHIP, FEDERAL REGULATIONS PROHIBIT THE RELABELING, REPACKAGING, RESALE OR REDISTRIBUTION OF THE INDIVIDUAL CONTENTS OF THIS PACKAGE.

ADJUVANT, PRESERVATIVE, ANTIBIOTIC AND THIMEROSAL FREE

PRODUCT DESCRIPTION: Nobivac^® NXT Feline-3 Rabies is a freeze-dried injectable vaccine specific for rabies virus glycoprotein utilizing RNA particle technology.

Nobivac NXT Feline-3 Rabies Indications

This product has been shown to be effective for vaccination of healthy cats 12 weeks of age or older against rabies. Duration of immunity is at least 3 years after a repeat dose. For more information regarding efficacy and safety data, go to productdata.aphis.usda.gov.

Dosage and Administration

Transfer contents of the sterile diluent vial to the Nobivac^® NXT Feline-3 Rabies vial aseptically. Mix gently until dissolved. Administer 1 dose (0.5 mL) subcutaneously as early as 12 weeks of age, with a booster injection administered 1 year later. Revaccinate every 3 years.

Precautions

● Store at 2° - 8°C (35°-46°F).

● Do not freeze.

● Use new, non-chemically sterilized needles and syringes.

● Do not mix with other products, except as specified on the label.

● In case of human exposure, contact a physician.

Warnings

● Vaccinate only healthy, non-parasitized cats.

● This product has not been tested in pregnant animals.

● Do not administer to horses or other equine species.

● The use of a biological product may produce anaphylaxis and/or other inflammatory immune-mediated hypersensitivity reactions. Antidote: Epinephrine, corticosteroids, and antihistamines may all be indicated depending on the nature and severity of the reaction.

Intervet Inc. d/b/a Merck Animal Health, Omaha, NE 68103 USA

VLN 165A/PCN 1905.D1

1 800 224-5318 (USA)

1 866 683-7838 (Canada)

For patent information:

http://www.merck.com/product/patent/home.html

CPN: 1208337.0